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Abstract Glucose-dependent insulinotropic polypeptide (GIP) 
plays an important role in the regulation of postprandial insulin 
secretion and proinsulin gene expression of pancreatic E-cells. 
This study demonstrates the molecular cloning of a cDNA for the 
GIP-receptor from a human insulinoma Agtll cDNA library. 
The cloned cDNA encoded a seven transmembrane domain pro- 
tein of 466 amino acids which showed high homology (41%) to 
the human glucagon-like peptide 1 (GLP-I) receptor. Homology 
to the GIP receptor from rat or hamster was 79% and 81%, 
respectively. When transfected stably into fibroblast CHL-cells 
a high affinity receptor was expressed which coupled to the 
adenylate cyclase with normal basal cAMP and increasing intra- 
cellular cAMP levels under stimulation with human GIP-I-42 
(ECso = 1.29 x 10 -13 M). The receptor accepted only human GIP 
1-42 (Kd = 1.93 + 0.2 × 10 -s M) and porcine truncated GIP 1-30 
(K d = 1.13 + 0.1 × 10 -s M) as high affinity ligands. At 1 pM, 
exendin-4 and (9-39)amide weakly reduced GIP-binding (25%) 
whereas secretin, glucagon, glucagon-like peptide-1, vasoactive 
intestinal polypeptide, peptide histidine-isoleucine, and pituitary 
adenylyl cyclase activating peptide were without effect. In trans- 
fected CHL cells, GIP-1-42 did not increase intracellular cal- 
cium. Northern analysis revealed one transcript of human GIP 
receptor mRNA with an apparent size of 5.5 kb. The exact 
understanding of GIP receptor egulation and signal transduction 
will aid in the understanding of the incretin hormone's failure to 
exert its biological action at the pancreatic B-cell in type II 
diabetes mellitus. 
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I. Introduction 
The postprandial release of gut hormones augments the insu- 
lin secretory response to a significant extent. We have learned 
that two peptide hormones are mainly responsible for this ef- 
fect, glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulin-releasing polypeptide (GIP) [1]. GLP-1 presently re- 
ceives attention as potential therapeutic tool for the treament 
of type II diabetes mellitus since it is still effective in such 
patients [1,2]. Interestingly, there is data which indicates that 
GIP has only a grossly reduced effect in diabetes [2]. This 
clearly is not the consequence of deficient GIP release since 
most studies indicate normal or even an increased GIP secre- 
tion in diabetes mellitus [3]. Still, such circumstance may con- 
tribute to the impaired r-cell function in diabetics. Therefore, 
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speculations about GIP receptor defects arose which find some 
support by a number of human diseases that can be attributed 
to point mutations in G protein-linked receptors [4,5,6]. Such 
defects alter either agonist binding, G protein-receptor interac- 
tions, or cause inproper membrane incorporation of the recep- 
tor [5,7]. In any case, cloning of the human GIP receptor is a 
prerequisite for its molecular characterization in diabetes. This 
was the objective of the present study. 
2. Experimental 
2.1. Materials 
All utilized peptides were purchased from Saxon Biochemicals (Ha- 
nover, Germany) or Peninsula (Frankfurt, Germany). '25I-labeled GIP- 
1-30 was prepared as earlier described [8]. The specific activity of the 
tracer was approx. 1500 Ci/mmol. Formamide, formaldehyde, 
50 x Denhardt's, and sonicated herring sperm DNA were obtained 
from Sigma, Deisenhofen, Germany. Multiprime labeling system, 
Hybond-N membrane and [c~32p]dCTP (spec. act. 110 TBq/mmol) were 
from Amersham, Braunschweig, Germany. For autoradiography gels 
were exposed to X-OMAT AR X-ray film (Kodak) at -80°C. Reverse 
transcriptase (Superscript Plus) and Taq-polymerase was obtained 
from Gibco BRL, Karlsruhe, Germany and from Boehringer, 
Mannheim (Germany), respectively. For subcloning, amplification and 
sequencing of DNA fragments the parental vector pGEM-3Z from 
Promega (Heidelberg, Germany) was used. For receptor binding stud- 
ies the human GIP receptor cDNA was cloned into the expression 
vector pTEJ-8, pTEJ-8 [9] was kindly donated by Siv Hjort, Copen- 
hagen (Denmark). Primer for reverse transcription (RT), polymerase 
chain reaction (PCR) and DNA sequencing were designed by us and 
manufactured byMWG-Biotech, Ebersberg, Germany. Sequenase was 
obtained from USB, Cleveland (USA). 
2.2. Molecular cloning of the human insulinoma GIP receptor cDNA and 
RT-PCR 
The human insulinoma random primed cDNA library [10] was 
screened with a radioactively abeled 1.1 kb Bg/lI-fragment of the rat 
GIP receptor cDNA [11] according to established protocols. In addition 
the same cDNA library was screened with a 5' specific fragment of the 
rat GIP receptor cDNA. This fragment (0.8 kb) was isolated from 1/lg 
total RNA of the rat insulinoma cell line RINm5F by RT-PCR using 
the primer 5'-AGCCAAGAAGCAGGTAGCAGC-3' (nucleotide po- 
sition 927-947) for reverse transcription and the primers 5'-TCCAG- 
CCCAACTGCCTCGA-3' (position 118-136) and 5'-GAGCGTCTC- 
ACAACCACC-3' (position 902-919, sequences deduced from [11] for 
cDNA amplification, respectively. Inserts of plaque-purified clones 
were released by EcoRI digest, subloned into pGEM-3Z and sequenced 
by the dideoxy chain termination method utilizing Sequenase. 
Partial human GIP receptor cDNA sequences were also isolated 
from 1/ag total RNA of a human insulinoma [12] using RT-PCR. The 
primers used were 5'-AGAATGCCAAGAATGCGG-3' (nucleotide 
position 945-962) for reverse transcription and the primers 5'-TCTC- 
TCGCCACACTGCTGC-3' (position 442-460) and 5'-CAAGATGG- 
TCATGAGGATGG-3' (position 906-924) for cDNA amplification, 
respectively. Reverse transcription was carried out according to the 
manufactures instructions. The cycling conditions for PCR were: 1 min, 
94 °C, 1 min 60°C and 1.5 min 72°C. 
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Fig. I. Northern blot analysis of GIP receptor expression i (A) tissue of a human insulinoma, colon, stomach cancer HGT 1 cells, and (B) transfected 
CHL cells. A 1.0 kb fragment of the insulinoma-derived GIP receptor cDNA was utilized as probe. In (A) only total RNA from the insulinoma showed 
a transcript of 5.5 kb. In transfected CHL cells stably expressing the GIP receptor (B) the expected signal at 2.6 kb was detected (arrows) for both 
the intact and the cDNA containing the alternatively spliced IIA62 fragment. 
2.3. RNA Isolation and Northern blot analys& 
Total RNA from human insulinoma tissue, stomach carcinoma HGT 
1-cells, and colon was isolated [12]. A 1.0 kb fragment of cDNA coding 
for human insulinoma GIP receptor was radioactively abeled. RNA 
was fractionated on 1% agarose gels containing 2.2 M formaldehyde, 
transfered to Hybond-N membranes and immobilized by UV cross- 
linking. RNA quantity was verified by reversibly staining membranes 
with methylene blue prior to hybridization. Hybridization was per- 
formed as described previously [10,13] and migration positions of the 
signals were calculated as compared to RNA markers. Final washing 
was in 0.1 xSSC at 65°C. 
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Fig. 2. Construction ofthe full-length clone (huGIPr) of the human GIP 
receptor, Alignment of overlapping partial cDNA clones. The cDNA 
fragments I, III and IV were obtained by screening of the human 
insulinoma cDNA library. The cDNA fragments II and IIA62 were 
amplified by RT-PCR from human insulinoma RNA. The full-length 
clone was constructed using the common restriction sites N (NheII), 
R (RcaI) and B (Bg/III). The hatched box indicates the 62 bp exon 
absent in the IIA62 alternative splice product coding for a truncated 
GIP receptor protein. ATG and TAG (IIA62) indicate translation i iti- 
ration and termination respectively. E = EcoRI. 
2.4. Cell transfections 
Recognition sequences of restriction enzymes present in overlapping 
sequences (Fig. 2) were utilized to combine the cDNA clones I, II, III 
and IV. For expression of the GIP receptor protein the full-length 
cDNA was cloned into the expression vector pTEJ-8. Stable cell clones 
which selectively expressed the insulinoma GIP receptor were estab- 
lished in Chinese Hamster Lymphoblast (CHL) cells by transfection 
using the calcium phosphate precipitation method (CellPhect Transfec- 
tion Kit, Pharmacia, Germany). Together with the receptor cDNA a 
resistence against geneticin (expression vector pTEJ-8) was introduced 
and, consequently, treated cells were screened and selected by their 
ability to resist against a geneticin treatment (final concentration 0.8 
mg/ml) and by their ability to specifically bind radiolabeled porcine 
GIP-1-30 with high affinity. 
2.5. Receptor b&ding studies 
Transfected cells were incubated for 30 min at 37°C with radiola- 
beled tracer (20,000 cpm) and unlabeled peptides in a final volume of 
330 /.tl. After incubation, the cell suspensions were centrifuged at 
12,000 x g, the radioactivity retained in the pellet was determined in a 
),-counter. Binding in the presence of an excess of unlabeled GIP 
(human GIP-142 or truncated porcine GIP-1-30) or other peptides (as 
indicated) was substracted in each experiment [10]. 
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Fig. 3. (A) Nucleotide sequence of the human GIP receptor cDNA 
(huGIPR). The deduced amino acid sequence (HUGIPR) is compared 
with the amino acid sequences of the GIP receptor cDNA from rat: 
RAGIPR [11] and hamster: HAGIPR [17]. Identical amino acids are 
indicated by (---) and gaps (/) were introduced to allow optimal align- 
ment. The 62 bp exon absent in one splice variant is indicated by v. (B) 
Comparison of the nucleotid sequence and the deduced amino acid 
sequence of the human GIP receptor cDNA and the truncated splice 
variant A62. The potential restiction site of the signal peptide is indi- 
cated by L 
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su~a~t  - - -  o ln  - - -  A la  A. ls  z l *  / A rg  Aan  A la  . . . . . . . . . . . .  M~ . . . . . .  Va l  . . . . . . . . .  450 
HA~PR Ar~ Zl Thr Oly  s~ Thr  . . . . . . . . . . . .  Pz~ . . . . . . . . . . . . . . .  G~U - - -  ~a l  41;? 
hUGIPR AGC CGG GA~ TTO ~A~ AGT TAC TG~ TA~ 1407 gggr~at~o~.=ga~9~o~gttc~tag~tggatgt ta t : tgagtg~o 
I~ZPR 9~ AEg GIu Leu Olu S~ T1"r Cym 4~6 
hu~ZP~ g 'cgocagg~acagtacqgagg&cgc  t : gggaaat :~gt  gaagga~acag~ . . . . .  Tg~c~atgc~t  ~ t : g g ~ F ~ t g a g ~ J ~  . . . . .  
huoz~st  ga~gt gaa=aaaa~t =~; t   ¢caca~a~go tat  ggaat ggt t a t ~  ~ o  tg~;a~F~t~au~ 
huOZ~R ~aggt~mcaa t taagc~t :~ccgaaagaggt  gaaagagat ~ t t tggggagag~tggagaa~.~p~t t~ga~ag~ttagg~a~ 
hU~ZPR,  a.ggoo~ t k.ggg 
V 
huozPR . . .GO¢ ~ ~ ac¢  ¢¢C 0CO CTT  ~TC OT¢ ATT  CCC ~ ~a ATC 128  
ImOZSU~ • . .01y  Tz 'p  01y  A la  PZO A im Z ,~ ~ Va l  ZZO PFO 2zp  VL1  Z]*e  271  
h~62 •. .GG~ T~ OOT OCT ~ AOC GC, A AC~ AAO TCA AG~ ~ TTT  ~ 121  
I~&S2 . . .G ly  Tz 'p  G ly  ~Ll.a G ly  ~ A I&  ~ Lys  I~  Azg  ]~zo  I~e  G ly  2" / I  
~ ,OZP]L  m'¢  A~ TA¢ C~ TAC ~ J~C ACO ¢~Y :UC T~. . .  
muozP~ ya l  Arg  Ty= I~u ~z  01u A~n ~ O ln  Cy l  ~ . . .  
huAs2  ~ TTA TAC ~ CCC ~ TCC Tr..L TWL a~ ta t : . . .  
~A62 U ly  Leu  T1"r  G1¥ P~ P~ S~ Set  284  
26 A. Volz et al./FEBS Letters 373 (1995) 23-29 
2.6. Measurement of cA MP 
Transfected CHL cells in KRB-buffer (105/300/zl) were incubated at 
37°C for 10 rain without or with various GIP-I~2 concentrations. 
After centrifugation for 2 min at 6000 × g, aliquots of the supernatants 
were used for the determination f cAMP levels by radioimmunoassay 
(Immunotech, Marseille, France). 
2. 7. Measurement of the cytosolic Ca :+ concentration 
Loading of cells (48 h after transfection) with the fluorescent calcium 
indicator fura-2 was performed as described [14,15]. Measurements of 
the [CaZ+]cyt concentration a d calibration of the data were performed 
essentially as described previously [14,15], using a modified Krebs- 
Ringer bicarbonate buffer containing 4 mM glucose and 1.5 mM CaC12. 
The measurements were performed at 37°C. Since CHL cells displayed 
dye efflux during the measurements, we corrected the data as described 
previously [14] using either addition of manganese and the manganese 
chelator diethylenetrianminepenta ace icacid (DTPA) in the beginning 
and at the end of each measurement, or performing the measurements 
in the presence of 250/IM sulfinpyrazone and adding manganese and 
DTPA. 
3. Results 
3.1. RNA isolation and Northern blot analysis 
Northern blot analysis of total RNA from human insulinoma 
tissue, human stomach carcinoma HGT-1 cells, and human 
colon was performed with a 1.0 kb cDNA probe (position -94 
to 924). GIP receptor mRNA with a calculated transcript size 
of 5.5 kb was detectable only in the insulinoma sample (Fig. 
1A). Furthermore, RNA from cells transfected with either GIP 
receptor- or truncated GIP receptor- (lacking a 62 bp exon; Fig. 
1B) cDNA was hybridized with the same probe. Transscript 
signals of expected sizes for both constructs were detected, i.e. 
approximately 2.6 kb for both. 
3.2. Cloning o f  a human insulinoma GIP receptor eDNA 
A human insulinoma Agt 11 cDNA library [10] was screened 
with a 0.8 kb PCR fragment located in the 5'region and a 1.1 
kb BgIIII fragment located in the 3' region of the rat GIP 
receptor cDNA [11]. Five different clones were isolated. Three 
of those (I, III, IV) were sequenced and used for the cloning 
of the functional human GIP receptor (Fig. 2). Two clones 
contained incompletely spliced cDNA sequences from the mid- 
dle portion of the human GIP receptor gene (data not shown). 
For determination of the completely spliced cDNA a RT-PCR 
fragment spanning this region was isolated from human insuli- 
noma total RNA (Fig. 2). The DNA sequence of this PCR 
fragment was identical to the coding region of the two incom- 
pletely spliced cDNA clones. Interestingly, an additional PCR 
product lacking a 62 bp exon was obtained (Fig. 2; IIA62). In 
this alternatively spliced product the predicted reading frame 
was shifted within the fourth transmembrane domain leading 
to a truncated GIP receptor protein (Fig. 3B). 
The sequence of the human GIP receptor cDNA (Fig. 3A) 
revealed a 1389 bp open reading frame encoding for a 466 
HUGIPR 



























HUPTHR MMGTARIAPGLALL  LC C PVL S S GYALVDADDVMT KEE 38 
M- - - TT S P I LQ~ LLLGLS LC GLL  LQRAET GS KGQTAG ELYQRWE RYRRECQ ET LAAAEPP-  S GLACNG S FDMYV-  CWDYAAPNATARASCPWYLPWHH 94 
MAGAPGP LRLAVLLLGMVG . . . .  RAG P RPQGATVS LWETVQKWREYRRQ CQRS LT E D P PPAT DLFCNRTFDEYA-  CWPD GEPGS FVNVSCPWYLPWAS 95 
M- -  PPCQPQRPLLLL  . . . .  LLLLACQPQVP-  SAQVMDFLFEKWKLY-  GDQCHHNLS LLPPPTELVCNRTFDKYS-CWPDT PANTTANI  SCPWYLPWHH 91 
M- RPHLS PPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGT EQPVPGCEGMWDN I SCWPS SVPGRMVEVECPRFLRMLT 98 
QI FLLHRAQAQCEKRLKEVLQRPAS IMES DKGWTSAST S GKP RKDKAS GKLYPES EEDKEAPTGS RYRGRPCL PEWDHI  LCWPLGAPGEVVAVPCPDY 136 
I II 
H%rAAG FVL RQCRSDGQW . . . . . . .  GLWRDHT QCEN P EKN EAFL  DQ RL I LE R- LQVMYTVGY SLSLATLLLAL  LI LS LFRRLHCTRNYI  H INLFTSFML 184 
SVPQGHVYRFCTAEGLWLQKCNS S LPWRDLS ECEES KRGERS S REEQLLF-  -LYI  IYTVGYALSFSALVIASAILLGFRHLHCTRNYIH IATLFASF I  L 191 
KVQH RFVFKRCGPDGQW-VRG P RGQ PWRDAS QCQMDGE I EVN KEVAKMY S S FQVMYTVGYSLSLGALLLALAI  LGG L S KLHCTRNAIHANLFASFVL  188 
S RNGS LFRNCTQ-DGWS ET FPRPNLACGVNVNDS SNEKRHSYLLK . . . . . . .  LKVMYTVGYSS SLVMLLVALGI  LCAFRRLHCTRNYIHMHLFVSF I  L 189 
I YDFNH KGHYRRCD RNG SWE LVP GHN RTWANYSECVKFLTN ET RE REVFD R- LGMI  YTVGYSVSLAS LTVAVL I  LAYFRRLHCTRNYIHMHLFLSFML 234 
I I I  IV  
RAAAI  LSRDRLLPRPGPYLGDQAL . . . . . . . . . . . . . . .  ALWNQALAACRTAQ IVTQYCVGANYTWLLVEGVYLHS LLVLVGGSE-  EGHFRYYLLLGW 266 
RALSVF IEDAALKWMYSTAAQQHQWDG . . . . . . . . . . . .  LLS YQGS L S CRLVFLLMQYCVAANYYWLLVEGVYLYTLLAFSVFSE-  QWI FRLYVS I GW 276 
KAS SVLVI  DGLLRTRYSQKI  GDD . . . . . . . . . . .  LSVS TWLS DGAVAGCRVAAVFMQYG I VANYCWLLVEGLYLHNLLGLATLPE-  RS FFS LYLGI  GW 274 
RALSNF IKDAVL . . . . . .  FSSDD . . . . . . . . . . . . . . .  VT  YCDAHRAGC KLVMVL FQYC IMANYSWLLVEGLYLHTLLA I  S FFSE RKYLQGS FVAFGW 280 
RAVS I FVKDAVLY S GAT LDEAE RLT EEEL RA IAQAP P P PATAAAGYAGCRVAVT F FLY FLATNYYWI  LVEGLYLHS LI FMAFFSEKKYLWGFTV-  FGW 331 
V VI 
GAPALFVI  PWVIVRYLYENT QCWERNEVKAIWWI  RTP I  LMT I L I NFL I  F IR I  LGI LLSKLRT RQ~IR- - - C RDYRVRLARSTLTLVP~P 361 
GVPLLFVVPWGIVKYLYE DEGCWT RNSNMNYWLI  IRLP I  L FAI GVNFL  I FVRVI  C IWSKLKAN LMC- - - KTD I KCRLAKSTLTL I  PLLGTHEVI  FAF  371 
GAPMLFVVPWAVVKCLFENVQCWT SNDNMG FWWI LRFPVFLA I  L INFF I  FVRIVQ LLVAKLRARQ~4H - - - HTDYKFRLAKSTLTL I  P L ~ A F  369 
GS PAI FVALWAIARH FLEDVGGWD INANAS IWWI IRGPVI  L S I L FNFI  LF IN I LRI  LMRKLRTQ ET R- GNQVS HYKRLARSTLLL I  PL  FGI HY IVFAF  377 
GLPAVFVAVWVSVRATLANTGCWD - L S S GNKKWI  I QVP I  LAS IVLNF I  LF IN IVRVLATKLRETNAG RCDT RQQYRKLLKSTLVLMPLFGVHYIVFMA 428 
VI I  
VT  EEQARGALRFAKLGFE I FLS SFQGFLVSVLYCF INKEVQSE I RRGWHHCRLRRS LGE EQRQL P ERLFRAL  P S GSGP GEVPT SRGLS S GTL P G P GNE 459 
VMDEHARGTLRF IKLFTELS  FTSFQGLMVAI  LYCFVNNEVQLE FRKSWERWRLEHLH I QRD S SMKP LKC PT S S L S SGATAGS SMYTATCQAS CS 463 
VT DEHAQGTLRSAKLFFDL  FLS S FQGLLVAVLYCFLNKEVQSELRRRWHRWRLG KVLWEERNT S NH RAS S S P GH GP P S KE LQ FGRGGG S QDS SAET PL 467 
SPEDAMEIQ . . . . .  LFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLRE FP LH PVAS F SN S T KAS HLEQSQGTCRT S I I 455 
T PYT EVS GTLWQVQMHYEML FNSFQGFFVAI  I YCFCNGEVQAE I NKCWSRWTLALD FKRKARS GS S S YS YG PMVS HT SVTNVG PRVGLGL P L S P RLL  P 526 
A~RELESYC 466 
AGGLPRLAESPF  477 
TATTNGHPQLPGHAKPGT PALETLETT  P PAMAAPKDDGFLNGS CS GLD~EASGPERP PALLQEEWETVM 593 
Fig. 4. Comparison of the deduced amino acid sequences of the human GIP receptor, human GLP-I receptor [10], human glucagon receptor [28], 
human secretin receptor [29] and the human parathormone receptor [30]. The predicted transmembrane domains are indicated by roman numbers. 
Amino acids which are conserved in more than two receptors are indicated with bold letters. 
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Fig. 5. (Upper panel) Displacement of['25I]GIP-1-30 binding to stably 
transfected CHL cells by unlabeled human GIP-1-42 (hGIP-142) and 
porcine truncated GIP-1 30 (pGIP-1-30). CHL cells were transfected 
with human GIP receptor full-length eDNA in pTEJ-8. Data shown are 
means + S.E.M. (n = 6), respectively. (Lower panel) hGIP-I~,2 in- 
duced cAMP production in CHL cells transfected with the human 
insulinoma GIP receptor. Data shown are means + S.E.M. (n = 6). 
amino acid comprising protein with a predicted start codon 
surrounded by an almost perfect ranslation initiation side (10 
bp identical to the 13 bp-consensus sequence; [16]). The human 
GIP receptor shows 79% and 81% homology to the rat receptor 
[11] and the hamster eceptor protein [17], respectively. The 
potential cleavage site between Gln2, and Argz2 [18] of the 
apparent signal peptide is conserved among the rat and human 
GIP receptor species (Fig. 3A). A comparison of the human 
GIP receptor with other members of the secretin/VIP/glucagon- 
receptor family showed that the seven predicted transmem- 
brane domains are highly conserved (Fig. 4). Based upon se- 
quence comparison the GIP receptor is closest related to the 
glucagon receptor (46%) and the GLP-1 receptor (41% homol- 
ogy). 
3.3. Specific binding of  GIP to transfected cells 
To confirm that the amplified receptor cDNA was appropri- 
ately expressed in CHL cells, binding analysis was performed 
with hGIP-IM2 and truncated pGIP-1-30. Furthermore, 
exendin-4, exendin-(9-39) amide [19], and several members of 
the glucagon-secretin-VIP peptide family were utilized for com- 
petition experiments at concentrations of 1 pM. Expression of 
the GIP receptor conferred specific binding of 125I-labeled GIP- 
1 30 upon CHL cells which was inhibited in a concentration- 
dependent manner by both, GIP-1 30 (K a -- 1.13 + 0.1 x 10 -8 
M) and GIP-1-42 (Ka = 1.93 + 0.2 x 10 -8 M) (Fig. 5). Analysis 
of the data by the Scatchard method indicated the presence of 
a single class of binding sites. Vasoactive intestinal peptide 
(VIP), GLP-1, glucagon, pituitary adenylyl cyclase activating 
peptide (PACAP) -27 and -38, peptide histidine-isoleucine 
(PHI), and secretin (all at 1 pM) did not displace 125I-labeled 
GIP-1-30 binding (Fig. 6). Only the exendins (-4 and -(9-39) 
amide) had a small but significant effect (approximately 25% 
reduction of labeled GIP-(1-30) binding; P < 0.05 for both 
exendins; t-test). Transfection of the alternatively spliced 
cDNA product IIA62 did not reveal any binding of GIP to the 
cells (data not shown) although a specific transcript was de- 
tected (Fig, 1B). 
3.4. Effect of GIP on cyclic AMP concentration i transfected 
cells 
To verify that the cloned receptor signaled through the ade- 
nylyl cyclase system, the effects of human G IP - I~2 on cAMP 
levels in transfected CHL cells were examined. GIP increased 
in a dose-dependent manner cAMP content in the transfect- 
ed cells (Fig. 5). The cAMP level rose to 280% above basal 
level by stimulation with 10 -'2 M GIP, and to 380% above basal 
level with 10 -'° M GIP. The ECs0 was approximately 
1.29 + 0.29 x 10 -.3 M. Concentrations ofGIP  > 10 -9 M, higher 
than those maximally stimulating cAMP production, showed 
a certain saturation of stimulation accompanied with a slight 
reduction of the effect. At the supramaxirnal concentration of
10 6 M GIP, cAMP was still increased 300% above basal. There 
was no increase of cAMP in mock transfected cells. 
3.4. Effects of GIP on cytosolic Ca :+ concentration i
transfected cells 
In the stably transfected CHL cells, human G IP - I~2 (at 
concentrations of 10 -'° to 10 -8 M) exerted no effect on [CaZ+]cyt 
concentration. In control experiments, depletion of intracellu- 
lar calcium stores by 1 pM thapsigargin clearly raised [Ca2+]cyt 
concentration (Fig. 7). 
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Fig. 6. Ligand screen of the cloned GIP receptor stably expressed in
CHL cells. Peptides were utilized at 1 pM to compete with [~25I]GIP-1- 
30 binding. Each peptide was tested 6 times. As control, hGIP-142 
abolished tracer binding. Both exendins had a significant effect 
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Fig. 7. hGIP-I~2 (at concentrations of 10 -~° to 10 -8 M) had no effect 
on [Ca2+]cyt concentration i the stably transfected CHL cells. Shown 
is a representative experiment at 10 -9 M GIP (n = 6). Depletion of 
intracellular calcium stores by 1 pM thapsigargin clearly raised [Ca2+]cyt 
concentration. 
4. Discussion 
A eDNA encoding the human GIP receptor was isolated 
from a insulinoma cDNA library. Previously, we have utilized 
this library to clone the human GLP-1 receptor [10]. Both 
receptors belong to a subfamily of the 7 transmembrane do- 
main receptors, also comprising the receptors for glucagon, 
parathormon, secretin, and vasoactive intestinal polypeptide, 
among others. Previously, Usdin et al. isolated a rat cDNA 
encoding the GIP receptor [11]. This eDNA served as template 
for our studies which revealed the molecular features of a GIP 
receptor expressed in human insulinoma tissue. Analysis of the 
deduced amino acid sequence and comparison with the recently 
published sequences from rat [11] and hamster [17] receptors 
revealed high homology between GIP receptors in various spe- 
cies. 
The recombinantly expressed insulinoma-derived human 
GIP receptor is coupled to the adenylate cyclase system. We 
found a clear increase of cAMP in response to GIP stimulation. 
This reflects the physiological situation where cAMP poten- 
tiates glucose-stimulated insulin secretion [1]. 
Addition of GIP induced no increase of [Ca2+]c, in stably 
transfected CHL cells. These results uggest that in contrast to 
the evident coupling to adenylate cyclase there was no relevant 
interaction of the insulinoma GIP receptor with the phospho- 
lipase C system. Our results are in accordance with previous 
observations concerning the signal transduction of the other 
insulinotropic gut hormone, GLP-1, in endocrine pancreatic 
beta cells and insulin-secreting cell lines. GLP-1 did not elevate 
[Ca2+]cyt a  all in RINm5F rat insulinoma cells [20], and it raised 
[Ca2+]cyt in rat islet fl cells [21] and in HIT hamster insulinoma 
cells [22] only via an indirect, glucose-dependent action, proba- 
bly involving cAMP-mediated activation of L-type voltage- 
dependent calcium channels. A similar scenario is probably in 
effect for the closely related GIP receptor. 
The recombinant insulinoma GIP receptor showed specific 
binding characteristics. High affinity binding was only found 
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for human GIP-1-42 and truncated porcine GIP-1-30. This is 
of interest since both peptides were very recently characterized 
as stimulators of proinsulin gene transcription [23]. Interest- 
ingly, exendin-4 and exendin-(9-39) amide, both considered 
potent ligands at the GLP-1 receptor [19], bound weakly at the 
GIP receptor whereas ecretin, glucagon, vasoactive intestinal 
polypeptide, peptide histidin-isoleucine, and pituitary adenylyl 
cyclase activating peptide were ineffective. This could reflect 
the close relationship of the GIP and the GLP-1 receptors as 
demonstrated bythe 41% amino acid sequence homology of the 
binding proteins. However, GLP-1 was not effective in compet- 
ing with labeled GIP for binding. Furthermore, in the in vivo 
situation an effect of the exendins at the GIP receptor is highly 
unlikely to occur [24]. 
With the sequence of the human GIP receptor known and 
the cDNA available, more work needs to be undertaken to 
evaluate whether GIP receptor mutations may contribute to the 
development of diabetes mellitus. The expression of receptors 
in diseased tissue provides an approach to correlate the struc- 
ture of receptors with cell function [7,25,26]. Actually, discrete 
mutations in several diseases, sporadic pituitary and thyroid 
tumors, McCune-Albright syndrome, in adrenal and ovarian 
tumors result into an altered signal transduction [7,27]. In any 
case, such studies are now easily to perform and may expand 
our knowledge about the pathophysiology of type II diabetes. 
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